麦克马斯特大学的AI迅速发现了肠醇,这是一个有前途的抗生素,它针对有害的肠道细菌,同时不影响有益的细菌,可能为克罗恩氏病和类似疾病提供更安全的治疗方法. AI at McMaster University rapidly discovered enterololin, a promising antibiotic targeting harmful gut bacteria while sparing beneficial ones, potentially offering safer treatment for Crohn’s and similar conditions.

麦克马斯特大学的研究员琼恩·斯托克斯(Jon Stokes)利用AI(AI)来识别潜在的新抗生素、肠蛋白林(Interololin),它针对E. Coli等有害肠道细菌,而不会损害有益的微生物,为治疗克罗恩病和其他炎症提供了希望。 A McMaster University researcher, Jon Stokes, used AI to identify a potential new antibiotic, enterololin, that targets harmful gut bacteria like E. coli without damaging beneficial microbes, offering hope for treating Crohn’s disease and other inflammatory bowel conditions. 人工智能在两分钟内预测了有效的化学结构和机制，将发现时间从数年缩短到数月，成本从数百万美元缩短到 60,000 美元。 The AI predicted effective chemical structures and mechanisms in under two minutes, cutting discovery time from years to months and costs from millions to $60,000. 6个月中由人类主导的验证证实了这些结果,突出表明需要专家监督。 Human-led validation over six months confirmed the results, highlighting the need for expert oversight. 加拿大的IBD患者人数预计将从320,000人增加到近470,000人,这一突破是朝着更安全、更有针对性的治疗迈出的重要一步,尽管仍然需要进行人类试验。 With Canada’s IBD patient numbers projected to rise from 320,000 to nearly 470,000, the breakthrough represents a major step toward safer, more targeted treatments, though human trials are still needed.